The UK’s Medicines & Healthcare products Regulatory Agency released its business plan for 2018-19 — the first year of the agency’s five-year Brexit plan outlining how it plans to operate post-Brexit.
The five-year plan aims to beef up internal and external alliances to ensure that the transition is smooth, while protecting public health, facilitating innovation, and minimizing the burden on industry.
To meet these goals, the agency will ensure that all legislation is transposed into UK law by March 30, 2019. National IT portals and databases will continue to operate and they will be flexible enough to enable information exchange with EU portals.
The agency also plans ongoing participation in the EU regulatory network, committees and working groups.